BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ACMELAB

All Eps Dividend Board Agm Q1 Q2 Q3

ACMELAB 02-Nov-2020

Ms. Tasneem Sinha, one of the Directors of the Company, has expressed her intention to buy 1,33,300 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE) within next 30 working days.

ACMELAB 15-Oct-2020

The Company has informed that they had launching of Zolpidem (5 mg. and 10 mg.) tablet in the US Market through contact manufacturing. It is to be noted that exploring in the US Market has been one of the ACME?s most ambitious and dream projects which will generate yearly earnings of US $ 50,000.00 approximately.

ACMELAB 15-Oct-2020

There will be no price limit on the trading of the shares of the Company today (15.10.2020) following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.

ACMELAB 15-Oct-2020

The Board of Directors has recommended 25% cash dividend for the year ended on June 30, 2020. Date of AGM: 10.12.2020, Time: 11:30 AM, Venue: Digital Platform. Record Date: 10.11.2020. The Company has also reported EPS of Tk. 6.85, NAV per share of Tk. 90.00 and NOCFPS of Tk. 5.42 for the year ended on June 30, 2020 as against Tk. 6.81, Tk. 86.69 and Tk. 7.81 respectively for the same period of the previous year.

ACMELAB 07-Oct-2020

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 14, 2020 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.

ACMELAB 09-Sep-2020

Mr. Mizanur Rahman Sinha, one of the Sponsor Directors of the Company, has further reported that he has completed his transfer of 35,16,446 shares to his daughter Ms. Tasneem Sinha, another Director of the Company, by way of gift outside the trading system of the Exchange as per declaration disseminated on 02.09.2020.

ACMELAB 09-Sep-2020

Ms. Jahanara Mizan Sinha, one of the Sponsor Directors of the Company, has further reported that she has completed her transfer of 35,16,672 shares to her son Mr. Tanveer Sinha, another Director of the Company, by way of gift outside the trading system of the Exchange as per declaration disseminated on 02.09.2020.

ACMELAB 02-Sep-2020

Ms. Jahanara Mizan Sinha, one of the Sponsor Directors of the Company, has expressed her intention to transfer 35,16,672 shares out of his total holding of 1,05,19,744 shares to her son Mr. Tanveer Sinha, another Director of the Company, by way of gift outside the trading system of the Exchange within 30 working days from the date of issuance of approval letter by DSE.

ACMELAB 02-Sep-2020

Mr. Mizanur Rahman Sinha, one of the Sponsor Directors of the Company, has expressed his intention to transfer 35,16,446 shares out of his total holding of 2,07,61,565 shares to his daughter Ms. Tasneem Sinha, another Director of the Company, by way of gift outside the trading system of the Exchange within 30 working days from the date of issuance of approval letter by DSE.

ACMELAB 07-Jun-2020

(Q3 Un-audited): EPS was Tk. 1.68 for January-March 2020 as against Tk. 1.74 for January-March 2019; EPS was Tk. 5.34 for July 2019-March 2020 as against Tk. 5.43 for July 2018-March 2019. NOCFPS was Tk. 3.97 for July 2019-March 2020 as against Tk. 5.15 for July 2018-March 2019. NAV per share was Tk. 88.48 as on March 31, 2020 and Tk. 86.69 as on June 30, 2019.

Previous Next page